Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance
Crossref DOI link: https://doi.org/10.1038/s41598-021-96159-0
Published Online: 2021-08-16
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dehghanian, Fariba
Alavi, Shahryar
Text and Data Mining valid from 2021-08-16
Version of Record valid from 2021-08-16
Article History
Received: 24 April 2021
Accepted: 5 August 2021
First Online: 16 August 2021
Competing interests
: The authors declare no competing interests.